A side-by-side comparison of two Healthcare investors: New Enterprise Associates (Power Score 80/100) and Vivo Capital (Power Score 83/100), both ranked among the most active firms tracked in this category.
| New Enterprise Associates | Vivo Capital | |
|---|---|---|
| Power Score™ | 80/100 | 83/100 |
| Assets Managed | $25B+ | $6.1B ("Active AUM" as of Q4 2025, the label the firm uses on its own homepage; it separately stated approximately $5.3B of regulatory assets under management in its 7 May 2025 fund-close announcement) |
| Founded | 1977 | 1996 |
| Headquarters | Menlo Park, CA | Palo Alto, CA |
| Sectors | Technology, Healthcare, Life Sciences | Healthcare, Biotech, Pharmaceuticals, Life Sciences, Healthtech |
NEA was founded in 1977 by three men who each brought a different piece of the puzzle: Dick Kramlich, who had trained under legendary investor Arthur Rock; Frank Bonsal, an investment banker who had taken startups public; and Chuck Newhall, who had managed investment funds at T. Rowe Price. Deliberately built with offices on both coasts from day one - unusual for the era - NEA's first fund raised just $16 million, a fraction of the more than $25 billion it manages today.
View full New Enterprise Associates profile →Vivo Capital describes itself as a global healthcare specialist running a multi-strategy investment platform that covers venture capital, private equity and public equity. Its investment strategy page names three distinct strategies: the Vivo Innovation Fund, which invests in venture-stage companies developing healthcare technologies or products; Vivo Capital Private Equity, which combines growth capital for companies at commercial inflection points with a buyout strategy covering leveraged buyouts, management buyouts, spin-offs and restructurings; and the Vivo Opportunity Fund, a long-only strategy investing primarily in global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies through follow-ons, PIPEs, registered directs and IPOs. The firm states it has invested in over 460 healthcare companies and operates from Palo Alto with offices in China and a presence in Singapore.
View full Vivo Capital profile →